IP Library Granted Patent US 10,105,324
Granted Patent B2
US 10,105,324 · App. 15/796,938 · Granted Oct 23, 2018

Immediate release oral guaifenesin solution

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,105,324
App. No.
15/796,938
Granted
Oct 23, 2018
Kind
B2
Abstract

Disclosed is a method of treating or ameliorating a condition which can be treated or ameliorated by the administration of guaifenesin, which method comprises orally administering to a subject in need thereof an effective amount of an immediate release solution for oral administration of guaifenesin and at least one additional drug. In addition to water the solution comprises as solvents propylene glycol and glycerol in a concentration which significantly increases the bioavailability of guaifenesin in the human body.

Claims (20)

1. A method of treating or ameliorating cough or cold, wherein the method comprises orally administering to a subject in need thereof an effective amount of an immediate release solution for oral administration of guaifenesin and one or more additional drugs which comprise at least one of an antitussive, a decongestant, an antihistsamine or an analgesic, which solution comprises as solvents water and a total of from 48% to 72% by weight, relative to a total weight of the solution, of propylene glycol and glycerol, and, when orally administered to an adult human subject as a single dose in an amount which affords 200 mg of guaifenesin, provides (i) a C max of at least 3600 ng/mL of guaifenesin and/or an AUC (0-inf) of guaifenesin of at least 3700 ng·hr/mL and (ii) a therapeutically effective plasma concentration of guaifenesin for at least 4 hours.

2. The method of claim 1 , wherein the solution comprises a total of from 54% to 66% by weight of propylene glycol and glycerol.

3. The method of claim 1 , wherein a weight ratio of glycerol to propylene glycol is from 1.7:1 to 2.5:1.

4. The method of claim 1 , wherein the solution comprises from 15% to 23% by of propylene glycol.

5. The method of claim 1 , wherein the solution comprises from 33% to 49% by weight of glycerol.

6. The method of claim 1 , wherein the solution provides a C max of at least 3800 ng/mL of guaifenesin.

7. The method of claim 1 , wherein the solution provides a C max of at least 4000 ng/mL of guaifenesin.

8. The method of claim 6 , wherein the solution provides an AUC (0-inf) of guaifenesin of at least 3900 ng·hr/mL.

9. The method of claim 7 , wherein the solution further provides an AUC (0-inf) of guaifenesin of at least 4100 ng·hr/mL.

10. The method of claim 1 , wherein the one or more additional drugs comprise a decongestant.

11. The method of claim 10 , wherein the decongestant comprises at least one of pseudoephedrine and a pharmaceutically acceptable salt thereof.

12. The method of claim 10 , wherein the decongestant comprises at least one of phenylephrine and a pharmaceutically acceptable salt thereof.

13. The method of claim 1 , wherein the one or more additional drugs comprise an antihistamine.

14. The method of claim 1 , wherein the one or more additional drugs comprise an analgesic.

15. The method of claim 1 , wherein the one or more additional drugs comprise an antitussive.

16. A method of treating or ameliorating cough or cold, wherein the method comprises orally administering to a subject in need thereof an effective amount of an immediate release solution for oral administration of guaifenesin and one or more additional drugs which comprise at least one of an antitussive, a decongestant, an antihistsamine or an analgesic, which solution comprises as solvents water and additionally propylene glycol and glycerol in a concentration which, when the solution is orally administered to an adult human subject as a single dose in an amount which affords 200 mg of guaifenesin, provides (i) a C max of guaifenesin which is higher than the C max of guaifenesin provided by an aqueous solution without propylene glycol and glycerol that comprises the same concentrations of guaifenesin and the at least one additional drug by a factor of at least 1.5 and/or an AUC (0-inf) of guaifenesin which is higher than the AUC (0-inf) of guaifenesin provided by the aqueous solution by a factor of at least 1.4 and (ii) a therapeutically effective plasma concentration of guaifenesin for at least 4 hours.

17. The method of claim 16 , wherein the solution provides a C max of guaifenesin which is higher than the C max of guaifenesin provided by an aqueous solution by a factor of at least 1.6 and an AUC (0-inf) of guaifenesin which is higher than the AUC (0-inf) of guaifenesin provided by the aqueous solution by a factor of at least 1.5.

18. The method of claim 17 , wherein the solution comprises a total of from 48% to 72% by weight of propylene glycol and glycerol, based on a total weight of the solution.

19. The method of claim 16 , wherein the one or more additional drugs comprise a decongestant.

20. The method of claim 16 , wherein the one or more additional drugs comprise an antihistamine and/or an antitussive.

Assignments (5)
SECURITY INTEREST Recorded Aug 27, 2021
From: AVION PHARMACEUTICALS, LLC; SOVEREIGN PHARMACEUTICALS, LLC; ACELLA HOLDINGS, LLC
To: CIBC BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 057310/0385 →
SECURITY AGREEMENT Recorded Jan 6, 2020
From: SOVEREIGN PHARMACEUTICALS, LLC
To: CIBC BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 051485/0571 →
RELEASE OF INTELLECTUAL PROPERTY SECURITY INTEREST Recorded Jan 3, 2020
From: MIDCAP BUSINESS CREDIT, LLC
To: SOVEREIGN PHARMACEUTICALS, LLC
Reel/Frame 051463/0377 →
SECURITY INTEREST Recorded Jan 3, 2019
From: SOVEREIGN PHARMACEUTICALS, LLC
To: MIDCAP BUSINESS CREDIT LLC
Reel/Frame 047890/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2018
From: HAFEY, PAUL
To: SOVEREIGN PHARMACEUTICALS, LLC,
Reel/Frame 045747/0017 →